For more than 20 years, Darnytsia has operated in accordance with international GMP standards — the same standards followed by leading global pharmaceutical companies. This means that Ukrainian medicines are manufactured with the same level of rigor, responsibility, and quality as products from international brands.
Darnytsia was among the first pharmaceutical companies in Ukraine to confirm compliance with international quality standards. Since then, the company has consistently adhered to these principles, continuously improving its technologies and production processes.
GMP (Good Manufacturing Practice) is a system of requirements governing the manufacture of medicines at every stage — from raw material sourcing to the release of finished products.
The quality of Darnytsia’s medicines is ensured by:
Advanced equipment: 14 automated production lines with a total manufacturing capacity of up to 670 million packages per year across 15 different dosage forms.
High-quality raw materials: The company works with verified suppliers from Europe and the Asia-Pacific region. All raw materials comply with the requirements of leading international pharmacopoeias and undergo multi-stage quality control.
Controlled processes: Multi-level quality control at every stage of production, including water purification from four in-house artesian wells reaching depths of up to 300 meters, as well as strict adherence to technological regulations.
Darnytsia continuously invests in advanced technologies, staff training, and laboratory facilities to ensure that every package meets the highest global standards.
Compliance with GMP requirements is the result of systematic daily work carried out across production facilities covering 11.5 hectares — equivalent to 16 football fields — guaranteeing the safety, efficacy, and reliability of every tablet.
Darnytsia demonstrates that Ukrainian pharmaceuticals can meet global standards. Every package is the result of teamwork, modern technologies, and a strong sense of responsibility to patients.
